Mathematical modeling of <i>JAK2V617F</i> clonal expansion in a general population cohort

The Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are a group of blood cancers characterized by overproduction of one or more types of blood cells, which can lead to thrombosis and other complications. MPNs develop slowly and are driven by a relatively small set of mutations in the hematopoietic stem cells (HSCs). Their slow development (over the course of decades) affords a unique opportunity to study their onset, but until recently few data have been available from individuals not yet showing overt disease. Thanks to the ambitious Danish General Suburban Population Study conducted in suburban Zealand, Denmark, we have identified a ( <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" overflow="scroll"> <mml:mrow> <mml:mi>n</mml:mi> <mml:mo>=</mml:mo> <mml:mn>67</mml:mn> </mml:mrow> </mml:math> ) cohort of individuals harboring the most common driver mutation in MPN (namely JAK2V617F ) and have obtained follow-up measurements of their variant allele fraction (VAF) spanning over 10 y. We show that these data are consistent with a Moran model governing the competition between healthy and mutated HSCs, and estimate the selective advantage of the mutant clone for each individual. Notably, we find that for many individuals, the change in VAF over many years is statistically consistent with zero, or even negative, selective advantage. This is in contrast to prior studies that have focused on patients diagnosed with overt MPN disease, in whom the mutant cells are almost always found to outcompete the healthy cells. Our results have implications for our understanding of the very early phases of MPN disease, and may contribute to early detection and personalized prediction of disease progression.

Authors

Institutions

Publication Details

Journal
Proceedings of the National Academy of Sciences
Published
2026-06-17
DOI
https://doi.org/10.1073/pnas.2507773123
Primary Topic
Myeloproliferative Neoplasms: Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Mathematical modeling of JAK2V617F clonal expansion in a general population cohort

Christina Ellervik, Johanne Gudmand‐Hoeyer, Thomas Stiehl, Johnny T. Ottesen et al.
Proceedings of the National Academy of Sciences
Myeloproliferative Neoplasms: Diagnosis and Treatment
article

Mathematical modeling of JAK2V617F clonal expansion in a general population cohort

Christina Ellervik, Johanne Gudmand‐Hoeyer, Thomas Stiehl, Johnny T. Ottesen, Jordan Andrew Snyder, Vibe Skov, Morten Andersen, Christina Schjellerup Eickhardt‐Dalbøge, M Lytken Larsen, Trine A. Knudsen, Hans C. Hasselbalch, Lasse Kjær
article en

Abstract

The Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are a group of blood cancers characterized by overproduction of one or more types of blood cells, which can lead to thrombosis and other complications. MPNs develop slowly and are driven by a relatively small set of mutations in the hematopoietic stem cells (HSCs). Their slow development (over the course of decades) affords a unique opportunity to study their onset, but until recently few data have been available from individuals not yet showing overt disease. Thanks to the ambitious Danish General Suburban Population Study conducted in suburban Zealand, Denmark, we have identified a ( <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" overflow="scroll"> <mml:mrow> <mml:mi>n</mml:mi> <mml:mo>=</mml:mo> <mml:mn>67</mml:mn> </mml:mrow> </mml:math> ) cohort of individuals harboring the most common driver mutation in MPN (namely JAK2V617F ) and have obtained follow-up measurements of their variant allele fraction (VAF) spanning over 10 y. We show that these data are consistent with a Moran model governing the competition between healthy and mutated HSCs, and estimate the selective advantage of the mutant clone for each individual. Notably, we find that for many individuals, the change in VAF over many years is statistically consistent with zero, or even negative, selective advantage. This is in contrast to prior studies that have focused on patients diagnosed with overt MPN disease, in whom the mutant cells are almost always found to outcompete the healthy cells. Our results have implications for our understanding of the very early phases of MPN disease, and may contribute to early detection and personalized prediction of disease progression.

Proceedings of the National Academy of SciencesVol. 123(25)
Roskilde University (DK), University of Copenhagen (DK), Boston Children's Hospital (US), Harvard University (US), North Carolina State University (US), Zealand University Hospital (DK), Westfälische Hochschule (DE)
Lundbeckfonden, TrygFonden, Region Sjælland, H. Lundbeck A/S
Openalex Percentile: Top 11%
Myeloproliferative Neoplasms: Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.